A Phase 2 interventional study of sildenafil in Sexual Dysfunctions, Psychological and Sexual Arousal Disorder, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 82 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Sexual Dysfunctions, Psychological with a site in United States — 3 open to participants now, 6 under way, none of them phase 3. Sexual Dysfunctions, Psychological · United States.
Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, this one is the 26th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2003, is one of 13 in phase 2, and was the 19th registered.
138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.
Browse Sexual Dysfunctions, Psychological studies →3 of the 62 studies in Sexual Dysfunctions, Psychological with a site in United States are open now. Recruiting first, the newest first:
Urological Research Network, LLC · Sites in United States
Ages 50–80 · Men only · Healthy volunteers
University of Illinois at Chicago · Sites in United States
Ages 18+ · Women only
San Diego Sexual Medicine · Sites in United States
Ages 21–75 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Sexual Dysfunctions, Psychological studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 16 · Phase 3 27 · Phase 4 2
First in 2002; this study’s year is marked. 3 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 267 is above the median of 100 across 114 interventional studies indexed under Sexual Dysfunctions, Psychological.
Median enrollment 196 across the 59 interventional studies, 18 across the 1 observational. Of the 53 that completed or were terminated, 20 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 62 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 1 study filed under Sexual Dysfunctions, Psychological — fewer than ten, so there is no comparison to draw.
2 of the studies in Sexual Dysfunctions, Psychological with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05777031University of MiamiSafety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease | 2027-01-15 |
| NCT06458049Dana-Farber Cancer InstituteSexual Health and Rehabilitation Online (SHAREonline) | 2027-05-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and toleration of oral sildenafil administered as required by women with Female Sexual Arousal Disorder (FSAD) who successfully complete one of the following Pfizer-sponsored, 12-week, double-blinded clinical trials: A1481082 or A1481123. Addition of this 52-week open-label extension will increase the total duration of sildenafil exposure to 64 weeks. Sustained efficacy will also be evaluated after 3 and 6 months of open-label therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: sildenafil
sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks
Safety/toleration of oral sildenafil.
Time frame: Continuous
The score for each of the individual questions 3,5 and 9 on the SQoL-F
Time frame: Week 14 and Week 26
The total satisfaction score on the Inventory of Treatment Satisfaction (ITS-modified EDITS)
Time frame: Week 14 and Week 26
The score for each of the individual questions 3,5,6 and 7 on the ITS-modified EDITS
Time frame: Week 14 and Week 26
The Arousal-lubrication Domain from the SFQ. The score for this domain is the sum of scores from Questions 11 and 12 from the SFQ
Time frame: Week 14 and Week 26
The Arousal-sensation Domain from the SFQ. The score for this domain is sum of scores from Questions 7,8,9 and 10 from the SFQ.
Time frame: Week 14 and Week 26
The total Quality of Life score on the Sexual Quality of Life (SQoL-F)
Time frame: Week 14 and Week 26
The Desire domain from the SFQ. Specifically, the sum of scores from questions 1,2,3,4,15 and 28 (frequency of pleasurable thoughts, wanted to be touched, wanted sex, initiated sex, had sex with penetration, looked forward to sex, respectively).
Time frame: Week 14 and Week 26
Question 16 from the SFQ at Weeks 14 and 26 (enjoyment of penetration and intercourse).
Time frame: Week 14 and Week 26
The Orgasm domain from the SFQ. The score for this domain is the sum of scores from questions 24,25 and 26 (orgasm frequency, level of pleasure and ease in achieving, respectively).
Time frame: Week 14 and Week 26
The individual questions of the Orgasm domain.
Time frame: Week 14 and Week 26
SFQ Question 27 (confidence as sexual partner).
Time frame: Week 14 and Week 26
SFQ Question 29 (disappointment with response).
Time frame: Week 14 and Week 26
Global Efficacy Question (SFQ Question 34, satisfaction with whole of sexual life)
Time frame: Week 14 and Week 26
The record gives a start of Jan 2003 and a completion of Feb 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Sexual Dysfunctions, Psychological →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →